Internal Medicine · Year 3 · from Internal Medicine

Case 2: Hospital-Acquired Pneumonia

Patient Presentation

A 72-year-old woman developed fever and increased oxygen requirements on hospital day 5. She was admitted for hip fracture repair and has been mobilizing slowly due to pain. She has a history of diabetes and chronic kidney disease. She has been receiving DVT prophylaxis and has a peripheral IV.

Vital Signs

  • Blood Pressure: 108/62 mmHg
  • Heart Rate: 105 bpm
  • Respiratory Rate: 26/min
  • Oxygen Saturation: 88% on 4L NC (was 96% on room air yesterday)
  • Temperature: 39.1°C

Physical Examination

  • General: Appears ill, somewhat confused
  • Pulmonary: Decreased breath sounds at right base, coarse crackles
  • Cardiovascular: Tachycardic
  • Skin: Surgical incision clean

Laboratory and Imaging

  • WBC: 18,500/μL with 15% bands
  • Creatinine: 2.1 mg/dL (baseline 1.5)
  • Chest X-ray: New right lower lobe infiltrate
  • Blood cultures: Pending
  • Sputum culture: Pending (purulent sputum obtained)

Clinical Image

Figure 2: Chest X-ray showing new right lower lobe infiltrate developing in a hospitalized patient, consistent with hospital-acquired pneumonia.

Image Source: Educational illustration for teaching purposes.

Questions

  1. What defines hospital-acquired pneumonia (HAP)?
  • A) Any pneumonia in a hospitalized patient
  • B) Pneumonia occurring ≥48 hours after hospital admission, not incubating at admission
  • C) Pneumonia in a patient with recent hospitalization
  • D) Pneumonia requiring ICU care
  1. What are the most common pathogens in HAP?
  • A) Streptococcus pneumoniae and Haemophilus influenzae
  • B) MRSA, Pseudomonas aeruginosa, and other gram-negative bacilli
  • C) Mycoplasma and Legionella
  • D) Influenza virus
  1. What is the appropriate empiric antibiotic regimen for HAP?
  • A) Azithromycin alone
  • B) Antipseudomonal beta-lactam; add MRSA coverage if risk factors present
  • C) Fluoroquinolone alone
  • D) Ampicillin-sulbactam
  1. What are risk factors for multidrug-resistant (MDR) pathogens in HAP?
  1. How does VAP differ from HAP in definition and management?

Answers

  1. B) Pneumonia occurring ≥48 hours after hospital admission, not incubating at admission - HAP is defined as pneumonia that develops ≥48 hours after hospital admission and was not incubating at the time of admission. This distinguishes it from CAP that becomes apparent after admission.
  1. B) MRSA, Pseudomonas aeruginosa, and other gram-negative bacilli - HAP pathogens differ from CAP:
  • Pseudomonas aeruginosa
  • MRSA
  • Klebsiella, Acinetobacter, Enterobacter
  • S. pneumoniae is less common in HAP
  1. B) Antipseudomonal beta-lactam; add MRSA coverage if risk factors present - Empiric therapy:
  • Antipseudomonal beta-lactam (piperacillin-tazobactam, cefepime, or meropenem)
  • Add vancomycin or linezolid if MRSA risk factors present
  • Add second gram-negative agent if high risk for MDR or high mortality risk
  1. Risk factors for MDR pathogens:
  • Prior IV antibiotic use within 90 days
  • Hospitalization >5 days before HAP onset
  • Prior MRSA infection or colonization
  • Structural lung disease (bronchiectasis, COPD)
  • High local prevalence of MRSA or resistant gram-negatives (>10-20%)
  • Septic shock
  • ARDS before HAP
  • Acute renal replacement therapy
  • Recent hospitalization (within 90 days)
  1. VAP vs. HAP:
  • VAP definition: Pneumonia developing >48 hours after endotracheal intubation
  • VAP pathogens: Similar to HAP but higher rates of Pseudomonas and Acinetobacter
  • VAP prevention: HOB elevation, daily sedation interruption, oral chlorhexidine, early mobilization, VAP bundles
  • VAP diagnosis: Can be challenging; clinical pulmonary infection score (CPIS) may help
  • Management: Similar empiric coverage; strongly consider MDR coverage

All cases for this lecture as Markdown